An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

June 24, 2020

Study Completion Date

June 26, 2020

Conditions

Healthy

Interventions

DRUG

Furosemide 80 mg (8 mg/mL)

Furoscix will be administered as a subcutaneous infusion.

Trial Locations (1)

Aventiv Clinical Research, Columbus